• Vera Therapeutics Inc (NASDAQ: VERA) has announced results from a prespecified per-protocol (PP) analysis of the Phase 2b ORIGIN trial of atacicept in IgA nephropathy (IgAN) patients.

• The company says the prior topline results, announced in early January, reflected the intent-to-treat (ITT) analysis of all randomized patients (n=116), which is a conservative assessment of efficacy.

• In the prespecified PP analysis, the population was defined as patients who had completed treatment according to the protocol (n=102).

• Fourteen patients across treatment arms with protocol violations were identified by a blinded third-party CRO and excluded.

• In the PP analysis, at Week 24, the atacicept 150 mg dose group achieved a 41% mean reduction in proteinuria versus baseline and a 34% delta versus placebo.

• With interim data at Week 36, the atacicept 150 mg dose group achieved a 47% mean reduction in proteinuria from baseline and a 48% delta versus placebo.

• Safety results indicated that atacicept was generally well-tolerated and was consistent with the previously observed safety profile of atacicept.

• Vera is continuing to rapidly advance atacicept into pivotal Phase 3 development, anticipated in the first half of 2023.

• Vera plans to prioritize and focus current resources on advancing atacicept in IgAN into a pivotal Phase 3 trial, extending the cash runway to the fourth quarter of 2024.

• This updated cash runway guidance assumes a delay in enrollment in the pivotal Phase 3 trial for lupus nephritis and a delay in the commitment of resources to the MAU868 program until a regulatory agreement is reached regarding the pivotal Phase 3 program for BK viremia in kidney transplant recipients.

• Price Action: VERA shares are up 3.55% at $9.05 during the premarket session on the last check Monday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article originally appeared on Benzinga.com

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.